LATEST ARTICLES

Manager of Scientific Programs and Initiatives

Job Title:        Manager, Scientific Programs and Initiatives Department:    Scientific Programs and Professional Education The Manager of Scientific Programs and Initiatives assists with the Foundation’s scientific programs and professional programs. This entails managing administratively the organization’s lymphoma consortia, initiatives, scientific workshops and programs. This includes but is not limited to on-site support of education programs and scientific...

Moah Soan, DVM, PhD

Home » Moah Soan, DVM, PhD Researcher Spotlight: Moah Soan, DVM, PhD ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI Jaime Peykoff Follicular Lymphoma Fellow Breakthrough therapies such as chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies have transformed the care of patients with follicular lymphoma (FL) such that many patients now experience deep and meaningful remissions. A...

Vignesh Shanmugam, MD

Home » Vignesh Shanmugam, MD Researcher Spotlight: Vignesh Shanmugam, MD BRIGHAM AND WOMEN’S HOSPITAL, INC. Tom Condon Family Fellow In many types of lymphoma, such as follicular lymphoma (FL), tumor cells are embedded in a rich microenvironment of non-malignant cells with which they regularly interact. The nature of these interactions has not been well studied, though, and Dr....

Michael Schneider, MD, PhD

Home » Michael Schneider, MD, PhD Researcher Spotlight: Michael Schneider, MD, PhD THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Treatment of lymphoma has been revolutionized by the development of chimeric antigen receptor (CAR) T-cell therapies, which elicit robust responses in many patients. However, a large number of patients still relapse after CAR T cell therapy, and Dr....

Benedikt Pelzer, MD

Home » Benedikt Pelzer, MD Researcher Spotlight: Benedikt Pelzer, MD WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY The Levine Family Fellowship Marginal zone lymphoma (MZL) is a slow-growing type of cancer that can eventually transform into a more aggressive diffuse B-cell lymphoma (DLBCL) in a subset of patients. Both MZL and DLBCL are characterized by a high frequency of...